EVMN
Evommune, Inc.
NYSE · usd
Evommune, Inc. (EVMN) trades at $6.88 (-1.99%) as of 7:13:04 PM EST on Nov 18, 2026, +27.88% over the past month. Market cap is $290.28M, with 3.0 days to cover in short interest.
Stock performance
How Evommune, Inc. (EVMN) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.99%
- 1W
- -20.19%
- 1M
- +27.88%
- YTD
- -59.81%
- 1Y
- -64.33%
- 52-wk range
- $4.94 – $33.20
Key statistics
Today's trading snapshot for EVMN: day range, open, previous close, volume and market cap.
- Day range
- $6.74 – $7.22
- Open
- $6.89
- Prev close
- $7.02
- Volume
- 600.36K
- Market cap
- $290.28M
- Shares out
- 41.35M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Evommune, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 1.15
- P/FCF
- —
- ROE
- -45.0%
- ROA
- -40.6%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 17, 2026
8-K filings
Material corporate events Evommune, Inc. has disclosed to the SEC on Form 8-K.
- Executive compensation changeNov 17, 2026
On November 13, 2026, the Compensation Committee ... approved the entry of an amendment to the applicable employment agreement(s) ... with certain executive officers of the Company, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer, pursuant to which ... such officer will be eligible to earn a cash retention award.
- Investor presentationNov 12, 2026
On November 12, 2026, the Company updated its corporate presentation to reflect certain business updates. The presentation is available in the "Investors & Media" section of the Company's website at ir.evommune.com, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
- Investor presentationNov 5, 2026
On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. The Company will make available a copy of the presentation from the webcast on the News & Events page of the Company's website at https://ir.evommune.com/news-events/ir-calendar.
- Underwriting agreementNov 4, 2026
Morgan Stanley & Co. LLC and Leerink Partners LLC acted as placement agents for the Private Placement ... The Company has agreed to pay the placement agents customary placement fees in their capacity as placement agents for the sale of the Shares to the Investors.
- Investor presentationSep 15, 2026
On September 15, 2026, Evommune, Inc. (the "Company") posted an updated corporate presentation on the "Company Info" page of the Company's website at https://ir.evommune.com/company-info/presentations. A copy of the presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
EVMN short interest
How heavily EVMN is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.0
- Short interest
- 3.39M
- Avg volume
- 1.15M
As of · reported to FINRA twice monthly.
EVMN news
The latest news and headlines about Evommune, Inc. (EVMN).
- Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue EstimatesnegativeZacks Investment Research· Nov 12, 2026
- Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsightpositiveGlobeNewswire Inc.· Oct 19, 2026
Frequently asked questions
What is the Evommune, Inc. (EVMN) stock price today?
Evommune, Inc. (EVMN) is trading at $6.88 (-1.99% on the day) as of 7:13:04 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Evommune, Inc.?
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative…
What is the short interest in EVMN?
As of Oct 30, 2026, EVMN has 3.39M shares short and 3.0 days to cover.
What exchange is EVMN listed on?
Evommune, Inc. (EVMN) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of EVMN with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a EVMN analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.